NousCom’s recent investment round for taking its cancer vaccine for clinical trial is a strong indicator of developments prevalent in vaccines market. Elaborating further, NousCom AG, based out of Switzerland, deploys the Exovax platform that uses single adenovirus vectors for encoding more than 100 neoantigens to create vaccines. Post the investment round, NousCom intends to utilize the capital to move over its cancer vaccine – the much-awaited NOUS-209, into phase 1/2 by 2018. In the event that the company accomplishes its goal, NOUS-209 may plausible be the first, off-the-shelf neoantigen cancer vaccine to debut in vaccines industry, that can be tested on humans. It has been touted that the company may be developing the vaccine in a bid to treat cancerous tumors defined by microsatellite instability in addition to preventing cancer in the carriers of the Lynch syndrome.
U.S. Vaccines Market, By Age Group, 2013 - 2024 (USD Billion)
In recent times, the prevalence of ailments such as hepatitis, DTP, human papilloma virus, polio, pneumococcal disease, dengue, cancer, influenza, rotavirus, and meningococcal disease have risen to an exponential extent. The growing need to prevent the incidences of such nearly fatal diseases has driven vaccines market giants to brainstorm newer medical technologies. While vaccines for dengue, hepatitis, influenza, and polio have been around for a while now, the recent years, in particular, have witnessed the growth of vaccines for terminal diseases such as cancer. Having recognized the potentially disastrous effects of being afflicted with cancer, numerous organizations and societies have been propagating screening programs and awareness activities that would, by all means, have a profound influence on cancer-based vaccines industry.
It is prudent to mention that therapeutic vaccines, in particular, have been gaining remarkable prominence of late, specifically due to rising efforts to combat adverse reactions due to conventional vaccines. In fact, therapeutic vaccination has received a considerable boost owing to the robust prevalence of cancer. Based on the disease occurrence rate close to half a decade back, it has been projected that more than 454 among 100,000 men and women are newly diagnosed with cancer every year. Around 39.6% of men and women are likely to be detected with cancer at some point of their lives. In the United States alone, cancer treatment spending has been forecast to cross a tentative USD 156 billion in 2020. The statistics seem alarming enough to prompt companies devise novel methodologies of cancer prevention – a globally induced move that may certainly propel vaccines market share in the years ahead. Recently in fact, the Germany-based biopharma firm, CureVac, had joined forces with pharma behemoth in order to develop five mRNA (messenger RNA) cancer vaccines. The deal is slated to bring forth a barrage of technologies in vaccines market, with Eli Lilly willing to shell out around USD 95 million (GBP 73 million) upfront and in equity. The companies are expected to jointly work on the development of vaccines based on CureVac’s mRNA technology – basically, mRNA molecules would be used to target tumor neoantigens that would induce anticancer immune responses. In essence, the deal would prove perpetually beneficial for the cancer-based industry, and is likely to bring about a transformation in vaccines market trends.
How the United States may emerge as a lucrative revenue pocket for vaccines market over 2017-2024
The United States has been deemed to be one of the most potentially remunerative regions for the growth of vaccines industry, given that the region is abound with the most sophisticated healthcare infrastructure and medical care personnel. Not to mention, the United States has a record of cancer, pneumococcal disease, Hepatitis B incidences, and the like, which has created a lucrative avenue for the development of vaccines market in the region. According to the National Foundation for Infectious Diseases (NFID), around 1 million of the U.S. adult populace are affected by pneumococcal pneumonia per year. An estimated 5% to 7% among them are expected to die of the disease, even as the death risk is said to be higher among patients beyond the age of 65. In response, vaccines market giants have already devised suitable preventive measures that can be administered to children, adults, and the elderly. However, surveys still indicate that not many in the U.S. have received a pneumococcal pneumonia, thereby paving the way for medical organizations to conduct awareness programs regarding the availability of the vaccine. In consequence, this would create an avenue for vaccines industry players to further develop and commercialize the vaccine to be used for the masses, thereby impelling U.S. vaccines market outlook.
It is prudent to mention that the U.S. Health & Human Services (HHS) has also been taking numerous initiatives to reduce the occurrence of infectious diseases by means of raising immunization rates, which would most certainly impact U.S. vaccines market share. Companies on the home turf have been vying with one another to manufacture innovative vaccines and obtain the much-revered FDA approval for the same. In fact, just recently, Dynavax Technologies Corp. declared that its HEPLISAV-B - Hepatitis B vaccine has been granted approval by the U.S. FDA to help prevent all the known types of Hepatitis B infection in adults. Driven by the robust efforts by medical companies, in conjunction with government initiatives for generating awareness regarding the significance of vaccination, U.S. held the largest share of the regional vaccines industry in 2016, and is expected to grow massively in the years to come.
Global vaccines market has been projected to experience a remarkable expansion in the years ahead. Driven by the escalating occurrence of potentially fatal diseases, companies partaking in vaccines market share have been bringing to fruition, a plethora of innovative technologies that may help prevent the masses from getting afflicted with dangerous ailments. As per estimates, vaccines industry size stood at a valuation of USD 32 billion in 2016, driven by the escalating demand for preventive vaccines worldwide. In recent times, the funding for vaccine-based R&D activities has also witnessed an inclined curve, which has led to the development of technologically advanced products and low-cost vaccines. In effect, with the rising number of awareness programs promoting routine vaccination and the growing popularity of combined vaccines, it is forecast that over the duration between 2017 and 2024, vaccines market share will grow at a CAGR of more than nine percent.